News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Allegro Ophthalmics LLC Announces Commencement of First Human Subject Study With ALG-1001 to Treat Vitreomacular Traction


11/4/2013 10:56:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced the commencement of a Phase II study of ALG-1001 in patients with vitreomacular traction (VMT).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES